Cellular therapies for spinal cord injury: What will the FDA need to approve moving from the laboratory to the human?

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

The transplantation of living cells and tissues to restore function and/or provide therapeutic molecules has been an active and ongoing area of research interest for over 25 years. Several of these potential therapies have reached initial clinical trials, and it is likely that applications will continue to expand, and that novel and improved approaches will be explored over the next several years. In the past, many of these experimental approaches were tested in early clinical trials without the oversight of regulatory agencies such as the Food and Drug Administration. However, as novel cellular therapies move from preclinical laboratory findings to the clinical arena, researchers and regulators face new and continually evolving issues and uncertainties involving long-term safety and efficacy. Using adrenal medullary transplantation in the spinal cord for pain as an example, this review presents an overview of past and current regulatory guidelines for moving these promising, novel cellular transplantation therapies from the laboratory to the human.

Original languageEnglish
Pages (from-to)71-79
Number of pages9
JournalJournal of Rehabilitation Research and Development
Volume40
Issue number4 SUPPL. 1
StatePublished - Jul 1 2003

    Fingerprint

Keywords

  • Cell transplantation
  • Center for Biologics Evaluation and Research (CBER)
  • Chromaffin cells
  • Food and Drug Administration (FDA)
  • Pain
  • Regulatory agencies
  • Spinal cord injury

ASJC Scopus subject areas

  • Rehabilitation
  • Health Professions(all)
  • Engineering(all)

Cite this